#ASCO14 - Poster: ARN-509 in patients with metastatic castration-resistant prostate cancer with and without prior abiraterone acetate treatment

CHICAGO, IL USA (UroToday.com) - Presented by Dana E. Rathkopf,1 Emmanuel S. Antonarakis,2 Neal D. Shore,3 Ronald Tutrone,4 Joshi J. Alumkal,5 Charles J. Ryan,6 Mansoor N. Saleh,7 Ralph J. Hauke,8 Rajesh Bandekar,9 Edna Chow Maneval,10 Carla J. de Boer,11 Mary B. Todd,12 Margaret K. Yu,13 and Howard I. Scher1 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 arn509 rathkopf thumb

1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY USA
2Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD USA
3Carolina Urologic Research Center, Myrtle Beach, SC USA
4Chesapeake Urologic Research Associates, Baltimore, MD USA
5Oregon Health and Science University, Knight Cancer Institute, Portland, OR USA
6University of California San Francisco, San Francisco, CA USA
7Georgia Cancer Specialists PC, Sandy Springs, GA USA
8Nebraska Cancer Specialists, Omaha, NE USA
9Janssen Research & Development, Philadelphia, PA USA
10Seragon Pharmaceuticals, San Diego, CA USA
11Janssen Biologics, B. V., Leiden, The Netherlands
12Janssen Global Services, Raritan, NJ USA
13Janssen Research & Development, Los Angeles, CA